featured
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab for Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Lancet Oncol 2022 May 27;[EPub Ahead of Print], C Antoniotti, D Rossini, F Pietrantonio, A Catteau, L Salvatore, S Lonardi, I Boquet, S Tamberi, F Marmorino, R Moretto, M Ambrosini, E Tamburini, G Tortora, A Passardi, F Bergamo, A Kassambara, T Sbarrato, F Morano, G Ritorto, B Borelli, A Boccaccino, V Conca, M Giordano, C Ugolini, J Fieschi, A Papadopulos, C Massoué, G Aprile, L Antonuzzo, F Gelsomino, E Martinelli, N Pella, G Masi, G Fontanini, L Boni, J Galon, C CremoliniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.